Refractive Error and Biometry in Retinopathy of Prematurity

Sponsor
San Ni Chen
Study ID
NCT03334513
Status
Completed

Conditions

  • Retinopathy of Prematurity

Eligibility Criteria

Sex
ALL
Age
3 Years - 3 Years
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    intravitreal injection of bevacizumab
  • Ranibizumab — DRUG
    intravitreal injection of ranibizumab

Study Details

The investigators compared long-term refractive and biometric outcomes in children with retinopathy of prematurity who received two different anti-vascular endothelial growth factor agents.

Key Dates

First listed
Nov 7, 2017
Start date
Apr 1, 2011
Status verified
Nov 2017
Primary completion
Apr 1, 2014
Completion
Apr 1, 2014

Study Design

Enrollment
35 participants (actual)

Arms

  • Arm: ROP group
    children with retinopathy of prematurity received either bevacizumab or ranibizumab

Primary Outcome Measure

spherical equivalent [ Time Frame: at corrected age of 3 year-old ]

Related Studies